Polymorphism of the p38 beta gene in patients with colorectal cancer
2014 (English)In: Oncology Letters, ISSN 1792-1074, E-ISSN 1792-1082, Vol. 8, no 3, 1093-1095 p.Article in journal (Refereed) Published
The p38 mitogen-activated protein kinase (MAPK) signaling pathways have been proposed to participate in the pathological process of cancer by affecting inflammation, proliferation, metastasis and cell survival. A single nucleotide polymorphism (SNP; rs2235356, -1628A -greater than G) in the promoter region of the p38 beta gene has been proposed as a genetic modifier for colorectal cancer (CRC) in a Chinese population. The present study evaluated the susceptibility of patients possessing this SNP to CRC, in addition to determining its association with clinical parameters in Swedish patients with CRC. Using the LightSNiP genotyping assay, this SNP was screened in 389 patients with CRC and 517 control subjects. No significant difference in the genotype distribution or in the allelic frequencies was identified between the two groups nor was any association identified with the clinical parameters. These findings indicate that the -1628A -greater than G polymorphism of the p38 beta gene is not significantly associated with a susceptibility to CRC in a Swedish population.
Place, publisher, year, edition, pages
Spandidos Publications , 2014. Vol. 8, no 3, 1093-1095 p.
p38 beta; promoter region; single nucleotide polymorphism; colorectal cancer
IdentifiersURN: urn:nbn:se:liu:diva-110697DOI: 10.3892/ol.2014.2315ISI: 000340854600024PubMedID: 25120664OAI: oai:DiVA.org:liu-110697DiVA: diva2:749244
Funding Agencies|Futurum; Academy for Healthcare; County Council (Jonkoping, Sweden) ; Foundation of Clinical Cancer Research (Jonkoping, Sweden) [110426-1]; University College of Health Sciences (Jonkoping, Sweden)2014-09-232014-09-192014-09-23